UDP-Glucuronosyltransferases 1A6 and 1A9 are the Major Isozymes Responsible for the 7-O-Glucuronidation of Esculetin and 4-Methylesculetin in Human Liver Microsomes

Esculetin (6,7-dihydroxycoumarin, ET) and 4-methylesculetin (6,7-dihydroxy-4-methylcoumarin, 4-ME) are typical coumarin derivatives that are attracting considerable attention because of their wide spectrum of biologic activities, but their metabolism remains unknown. This study aimed to elucidate the in vitro UDP-glucuronosyltransferase (UGT) metabolism characteristics of ET and 4-ME. 7-O-monoglucuronide esculetin (ET-G) and 7-O-monoglucuronide 4-methylesculetin (4-ME-G) were identified by liquid chromatography-mass spectrometry (LC-MS) and 1H-nuclear magnetic resonance (1HNMR) when ET or 4-ME was incubated with human liver (HLM) in the presence of UDP-glucuronic acid. Screening assays with 12 human expressed UGTs demonstrated that the formations of ET-G and 4-ME-G were almost exclusively catalyzed by UGT1A6 and UGT1A9. Phenylbutazone and carvacrol (UGT1A6 and UGT1A9 chemical inhibitors, respectively) at different concentrations (50, 100, and 200 μM) significantly inhibited the formation of glucuronidates of ET and 4-ME in HLM, UGT1A6, and UGT1A9 when the concentrations of ET and 4-ME ranged from 10 to 300 μM (P < 0.05). Clearance rates of ET in HLM, HIM, UGT1A6, and UGT1A9 were 0.54, 0.16, 0.69, and 0.14 ml/min/mg, respectively. Corresponding clearance rates values of 4-ME were 0.59, 0.03, 0.14, and 0.04 ml/min/mg, respectively. In conclusion, 7-O-monoglucuronidation by UGT1A6 and UGT1A9 was the predominant UGT metabolic pathway for both ET and 4-ME in vitro. The liver is probably the major contributor to the glucuronidation metabolism of ET and 4-ME. ET showed more rapid metabolism than 4-ME in glucuronidation.

[1]  D. Makhija,et al.  PP265—Attenuation of aluminium induced neurodegeneration by 4-methylesculetin , 2013 .

[2]  Andrew Rowland,et al.  The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. , 2013, The international journal of biochemistry & cell biology.

[3]  K. Saikia,et al.  Anticancer activity of esculetin via-modulation of Bcl-2 and NF-κB expression in benzo[a]pyrene induced lung carcinogenesis in mice , 2013 .

[4]  K. N. Venugopala,et al.  Review on Natural Coumarin Lead Compounds for Their Pharmacological Activity , 2013, BioMed research international.

[5]  N. Ashokkumar,et al.  Protective effect of esculetin on hyperglycemia-mediated oxidative damage in the hepatic and renal tissues of experimental diabetic rats. , 2013, Biochimie.

[6]  E. L. Maistro,et al.  Antigenotoxic effect of 4-methylesculetin on mice cells exposed to doxorubicin , 2012 .

[7]  D. Hadjipavlou-Litina,et al.  Coumarin-based drugs: a patent review (2008 – present) , 2012, Expert opinion on therapeutic patents.

[8]  Guangbo Ge,et al.  Investigation of UDP‐glucuronosyltransferases (UGTs) Inhibitory Properties of Carvacrol , 2012, Phytotherapy research : PTR.

[9]  E. Del Grosso,et al.  Identification of the Human UDP-Glucuronosyltransferases Involved in the Glucuronidation of Combretastatin A-4 , 2010, Drug Metabolism and Disposition.

[10]  Yan-Yan Zhang,et al.  Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Daphnetin , 2010, Drug Metabolism and Disposition.

[11]  S. Kok,et al.  Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. , 2009, Oral oncology.

[12]  Yiyi Hu,et al.  Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells , 2009, Immunopharmacology and immunotoxicology.

[13]  K. Kang,et al.  Protective effect of esculetin against oxidative stress-induced cell damage via scavenging reactive oxygen species , 2008, Acta Pharmacologica Sinica.

[14]  Yung-Hyun Choi,et al.  Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. , 2008, Toxicology and applied pharmacology.

[15]  V. Tam,et al.  Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. , 2007, Molecular pharmaceutics.

[16]  P. Soares-da-Silva,et al.  Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation , 2006, Drug Metabolism and Disposition.

[17]  V. Tam,et al.  Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties , 2006, Drug Metabolism and Disposition.

[18]  J. Miners,et al.  SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES , 2006, Drug Metabolism and Disposition.

[19]  K. Leung,et al.  Immunomodulatory effects of esculetin (6,7-dihydroxycoumarin) on murine lymphocytes and peritoneal macrophages. , 2005, Cellular & molecular immunology.

[20]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[21]  T. Kaneko,et al.  Suppression of lipid hydroperoxide-induced oxidative damage to cellular DNA by esculetin. , 2003, Biological & pharmaceutical bulletin.

[22]  J. Magdalou,et al.  Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. , 2003, Archives of biochemistry and biophysics.

[23]  T. Tseng,et al.  Inhibitory effect of esculetin on oxidative damage induced by t-butyl hydroperoxide in rat liver , 2000, Archives of Toxicology.

[24]  B. Lake,et al.  Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[25]  Y. Okada,et al.  Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. , 1995, Chemical & pharmaceutical bulletin.

[26]  J. Hoult,et al.  Inhibitory activity of a series of coumarins on leukocyte eicosanoid generation , 1994, Agents and Actions.

[27]  B. Halliwell,et al.  Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. , 1992, Biochemical pharmacology.

[28]  E. Ragazzi,et al.  Anti-inflammatory and peripheral analgesic activity of esculetin in vivo. , 1988, Pharmacological research communications.

[29]  Kiyoshi Yamaoka,et al.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[30]  D. Egan,et al.  The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. , 1990, Drug metabolism reviews.